Multicentre, Single-arm, Non-interventional Regulatory Post- Marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda for Weight Management in Routine Clinical Practice in Taiwan
Latest Information Update: 19 Dec 2024
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 12 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Apr 2024 Status changed from not yet recruiting to recruiting.
- 04 Mar 2024 New trial record